| Karolwood Gardens Richmond | |
| 1503 Michael Road, Richmond, Virginia 23229 | |
| (804) 288-6245 | |
| Name | Karolwood Gardens Richmond |
|---|---|
| Location | 1503 Michael Road, Richmond, Virginia |
| Certified By | Medicaid |
| No. of Certified Beds | 32 |
| Occupancy Rate | 75.31% |
| Medicare ID (CCN) | 49E151 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1588246557 |
| Organization Name | HENRICO VA OPCO LLC |
| Address | 1503 Michaels Rd, Henrico, VA 23229 |
| Phone Number | 804-288-6245 |
News Archive
BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).
Netezza Corporation, the global leader in data warehouse and analytic appliances, today announced that Marshfield Clinic, one of the largest private, multispecialty medical systems in the United States, has selected the Netezza® TwinFin™ appliance to address the research database and computation needs of the Marshfield Clinic Research Foundation.
Claims about the health benefits of foods and nutritional supplements have proliferated in recent years, most of them based on studies measuring ingredients' effects on biomarkers as substitutes for actual clinical outcomes.
EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
BioTime, Inc. today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM).
Netezza Corporation, the global leader in data warehouse and analytic appliances, today announced that Marshfield Clinic, one of the largest private, multispecialty medical systems in the United States, has selected the Netezza® TwinFin™ appliance to address the research database and computation needs of the Marshfield Clinic Research Foundation.
Claims about the health benefits of foods and nutritional supplements have proliferated in recent years, most of them based on studies measuring ingredients' effects on biomarkers as substitutes for actual clinical outcomes.
EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.09 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 82.35 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.89 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 16.98 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.25 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 18.18 | 14.2 |